Brief: Ultimovacs Provides Update From Phase I Study In Malignant Melanoma

Zelluna ASA

11/06/2024 06:14

June 11 (Reuters) - Ultimovacs ASA  ULTI.OL :
    * REG-ULTIMOVACS PROVIDES UPDATE FROM PHASE I STUDY IN
MALIGNANT
MELANOMA: CONTINUED STRONG OVERALL SURVIVAL IN PATIENTS TREATED
WITH  UV1 CANCER VACCINE AND PEMBROLIZUMAB
    * ALL PATIENTS IN TRIAL WHO WERE ALIVE AT 3 YEARS REMAIN
ALIVE AT
4 YEARS (69.5%) WITH A MINIMUM FOLLOW-UP PERIOD OF 4 YEARS
(MEDIAN 53.0 MONTHS)
    * EXPECTED NEXT KEY MILESTONE FOR UV1 IS READOUT OF FOCUS
TRIAL
DURING Q3 2024

Source text for Eikon:  ID:nGNE97kLvx 
Further company coverage:  ULTI.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))